Zacks Investment Research downgraded shares of SUNESIS PHARMA (SNSS) from OUTPERFORM to NEUTRAL on February 18, 2014, with a target price of $5.40.
Sunesis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. It has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. It is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on SUNESIS PHARMA (SNSS),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment